

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69152

**Title:** Efficacy and Safety of Argatroban in Treatment of Acute Ischemic Stroke: A meta-analysis

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05130664

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-06-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-07-16 15:19

**Reviewer performed review:** 2021-07-16 15:27

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear Authors very compliments for this issue. The authors demonstrated that the overall analysis result showed that there was no significance between the argatroban group and the control group (Risk ratio=1.34; 95%CI=0.66-2.74; P=0.42) (figure 4). The results indicated that argatroban does not increase the risk of bleeding in AIS. Please can the authors indicate if there are gender differences in these studies, in particular in adverse events (bleeding)?. However, the authors can indicate the role of age and comorbidity (renal and liver disease in particular) in the choice of treated population?

Best regards